Oragenics, Inc.’ Announces Fourth U.S. Patent Issued For MU1140(TM)

ALACHUA, Fla., Aug. 7 /PRNewswire-FirstCall/ -- Oragenics, Inc. , a biotechnology development company, announced that the US Patent office has issued a fourth patent (No. 7,067,125), that further describes the composition and uses of the company’s exclusively licensed novel antibiotic peptide, MU1140(TM). The patent claims include uses of the antimicrobial peptide for the treatment and prevention of bacterial infections.

Dr. Jeffrey Hillman, Oragenics’ Chief Scientific Officer and the inventor of the patented MU1140(TM) technology, stated, “This recently issued patent provides additional intellectual property protection for our lead antibiotic compound. MU1140(TM) represents a major new class of antibiotics and one day could become a clinically useful tool against those bacteria that have grown resistant to existing antibiotics.” Oragenics plans to complete by the end of this year the preclinical tests necessary to begin a human clinical trial with its promising molecule, MU1140(TM).

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas: infectious disease and oncology. Oragenics’ core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections and obesity. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics’ current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward- looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Oragenics, Inc.

CONTACT: Robert T. Zahradnik, Oragenics, +1-386-418-4018, ext. 222